

Title (en)
MEDICAMENT FOR TREATING CANCER

Title (de)
ARZNEIMITTEL ZUR BEHANDLUNG VON KREBS

Title (fr)
MÉDICAMENT UTILISÉ DANS LE TRAITEMENT DU CANCER

Publication
EP 3949990 A4 20230208 (EN)

Application
EP 20784328 A 20200331

Priority
• JP 2019070120 A 20190401
• JP 2020014832 W 20200331

Abstract (en)
[origin: EP3949990A1] The present invention provides a therapeutic agent and a therapeutic method for hepatocellular carcinoma, etc., capable of exerting a more potent and sustained antitumor effect than existing multikinase inhibitors. The present invention is directed to a pharmaceutical combination for treating hepatocellular carcinoma, which is characterized by comprising lenvatinib or a prodrug thereof, or a pharmacologically acceptable salt thereof, or a hydrate or solvate thereof, and an antibody against human DLK-1, which has in vivo antitumor activity, or an antibody fragment derived from the antibody.

IPC 8 full level
A61K 39/395 (2006.01); **A61K 31/47** (2006.01); **A61K 47/68** (2006.01); **A61P 1/16** (2006.01); **A61P 35/00** (2006.01); **A61P 43/00** (2006.01); **C07K 16/28** (2006.01); **C12N 15/13** (2006.01)

CPC (source: EP KR US)
A61K 31/47 (2013.01 - EP KR US); **A61K 39/395** (2013.01 - EP KR); **A61K 39/3955** (2013.01 - US); **A61K 45/06** (2013.01 - KR); **A61P 1/16** (2017.12 - EP); **A61P 35/00** (2017.12 - EP KR US); **A61P 43/00** (2017.12 - EP); **C07K 16/28** (2013.01 - EP KR); **A61K 2039/505** (2013.01 - KR); **A61K 2300/00** (2013.01 - KR); **C07K 2317/73** (2013.01 - EP)

Citation (search report)
• [A] US 2009299038 A1 20091203 - NAKAMURA KOJI [JP], et al
• [A] WO 2018146199 A1 20180816 - ADC THERAPEUTICS SA [CH], et al
• [A] PERSONENI NICOLA ET AL: "Lenvatinib for the treatment of unresectable hepatocellular carcinoma: evidence to date", JOURNAL OF HEPATOCELLULAR CARCINOMA, vol. Volume 6, 1 January 2019 (2019-01-01), pages 31 - 39, XP093004122, DOI: 10.2147/JHC.S168953
• [A] KUDO MASATOSHI: "Systemic Therapy for Hepatocellular Carcinoma: 2017 Update", ONCOLOGY : INTERNATIONAL JOURNAL OF CANCER RESEARCH AND TREATMENT, vol. 93, no. Suppl. 1, 19 December 2017 (2017-12-19), CH, pages 135 - 146, XP093004038, ISSN: 0030-2414, Retrieved from the Internet <URL:https://www.karger.com/Article/Pdf/481244> DOI: 10.1159/000481244
• [A] TSUCHIYA ATSUNORI ET AL: "Diverse perspectives to address for the future treatment of heterogeneous hepatocellular carcinoma", HELIYON, vol. 5, no. 3, 1 March 2019 (2019-03-01), GB, pages e01325, XP093004039, ISSN: 2405-8440, DOI: 10.1016/j.heliyon.2019.e01325
• See references of WO 2020204033A1

Designated contracting state (EPC)
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

DOCDB simple family (publication)
EP 3949990 A1 20220209; EP 3949990 A4 20230208; AU 2020255907 A1 20211028; CA 3135157 A1 20201008; CN 113660954 A 20211116; IL 286680 A 20211031; JP WO2020204033 A1 20201008; KR 20210144767 A 20211130; TW 202104259 A 20210201; US 2022193064 A1 20220623; WO 2020204033 A1 20201008

DOCDB simple family (application)
EP 20784328 A 20200331; AU 2020255907 A 20200331; CA 3135157 A 20200331; CN 202080026567 A 20200331; IL 28668021 A 20210926; JP 2020014832 W 20200331; JP 2021512150 A 20200331; KR 20217033277 A 20200331; TW 109110983 A 20200331; US 202017599820 A 20200331